Last updated on September 2017

"A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) "


Brief description of study

"A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) "

Detailed Study Description

The purpose of this study is to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab. Purpose of the study is also to evaluate the safety and tolerability of copanlisib. Approximately 567 patients will be randomly assigned in in blinded treatment arms copanlisib plus rituximab or placebo plus rituximab.

Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo dosing will be administered on the same days as copanlisib.

Rituximab dose is administered weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9. The maximum administration of rituximab is 8 times.

Copanlisib or placebo treatment will be continued until disease progression, unacceptable toxicity, or until another criterion is met for withdrawal from the study treatment.

Following the end of treatment visit, patients will enter either the Safety follow-up or the Active follow-up period.

The efficacy is measured by duration of progression-free survival (time between randomization and onset of a further progression of disease, or death from any cause). Progression of disease will be determined by radiologic tumor assessments to be performed at screening, as well as during the active follow up period tumor assessments every 8 weeks during Year 1, every 12 weeks during Year 2, and every 24 weeks during Year 3.

Blood samples will be collected for safety analysis and pharmacokinetic analysis. Archival tumor tissue and blood samples will be collected for biomarker analysis and for central pathology review, fresh biopsy tissue and bone marrow will be collected but not mandatory.

For Study Locations, Click Here

Clinical Study Identifier: TX153140

Find a site near you

Start Over

Research Center

Located in: Additional Locations, XX Argentina
  Connect »

Research Center

Located in: Additional Locations, XX Australia
  Connect »

Research Center

Located in: Additional Locations, XX Austria
  Connect »

Research Center

Located in: Additional Locations, XX Belgium
  Connect »

Research Center

Located in: Additional Locations, XX Brazil
  Connect »

Research Center

Located in: Additional Locations, XX Chile
  Connect »

Research Center

Located in: Additional Locations, XX China
  Connect »

Research Center

Located in: Additional Locations, XX France
  Connect »

Research Center

Located in: Additional Locations, XX Germany
  Connect »

Research Center

Located in: Additional Locations, XX Greece
  Connect »

Research Center

Located in: Additional Locations, XX Hungary
  Connect »

Research Center

Located in: Additional Locations, XX Ireland
  Connect »

Research Center

Located in: Additional Locations, XX Italy
  Connect »

Research Center

Located in: Additional Locations, XX Japan
  Connect »

Research Center

Located in: Additional Locations, XX Poland
  Connect »

Research Center

Located in: Additional Locations, XX Russian Federation
  Connect »

Research Center

Located in: Additional Locations, XX South Africa
  Connect »

Research Center

Located in: Additional Locations, XX Spain
  Connect »

Research Center

Located in: Additional Locations, XX Sweden
  Connect »

Research Center

Located in: Additional Locations, KY USA
  Connect »

Research Center

Located in: Additional Locations, PA USA
  Connect »

Research Center

Located in: Additional Locations, WA USA
  Connect »

Research Center

Located In: Additional Locations, XX Bulgaria
  Connect »

Research Center

Located In: Additional Locations, XX Colombia
  Connect »

Research Center

Located In: Additional Locations, XX Hong Kong
  Connect »

Research Center

Located In: Additional Locations, XX Republic of Korea
  Connect »

Research Center

Located In: Additional Locations, XX New Zealand
  Connect »

Research Center

Located In: Additional Locations, XX Singapore
  Connect »

Research Center

Located In: Additional Locations, XX Taiwan
  Connect »

Research Center

Located In: Additional Locations, MI USA
  Connect »

Research Center

Located In: Additional Locations, OH USA
  Connect »

Research Center

Located in: Additional Locations, XX Denmark
  Connect »

Research Center

Located in: Additional Locations, XX Slovakia
  Connect »

Research Center

Located in: Additional Locations, CT USA
  Connect »

Research Center

Located in: Additional Locations, UT USA
  Connect »

Research Center

Located In: Additional Locations, XX Mexico
  Connect »

Research Center

Located In: Additional Locations, XX Portugal
  Connect »

Research Center

Located in: Additional Locations, XX Belarus
  Connect »

Research Center

Located in: Additional Locations, XX Lithuania
  Connect »

Research Center

Located in: Additional Locations, XX Luxembourg
  Connect »

Research Center

Located in: Additional Locations, XX Malaysia
  Connect »

Research Center

Located in: Additional Locations, XX Philippines
  Connect »

Research Center

Located in: Additional Locations, XX Romania
  Connect »

Research Center

Located in: Additional Locations, XX Thailand
  Connect »

Research Center

Located in: Additional Locations, XX Turkey
  Connect »

Research Center

Located in: Additional Locations, XX Ukraine
  Connect »

Research Center

Located in: Additional Locations, XX Vietnam
  Connect »